Just do proper due diligence.
This company has done its best to obfuscate their history and only product to cover up a horrid past and scam retail investors.
Asensus is the third name that this company is operating under. Their prior names were Transenterix and SafeStitch, both of which have never recorded a profit since inception as SafeStitch in 2005.
Each “company” has had just one product that was FDA approved under each company name and every one of them failed to generate a single dollar.
SAFESTITCH; Had a product named “SafeStitch” which was a Low Anterior Bowel Resection anastomotic device used for surgical intervention (cancer removal). It simplified the process of a purse-string suture technique that was time consuming. After FDA approval, this product was welcomed into the OR by general surgeons and did save time. Unfortunately, within months, patients were experiencing sepsis and many died due to a failure of the suture leading to anastomotic leaks.
TRANSENTERIX; Had FDA approval of their “SPYDER” RASD (Robtic Assisited Surgical Device) which proved to be cumbersome and lacking efficacy. It was shelved after a “No Sale” opinion from surgeons and hospitals. SURGIBOT; another RASD attempt that the FDA denied.
Telap-ALF X (Renamed Senhance) was created in 2003 by a nuclear research company that SOFAR thought may be viable in a OR setting. They found that it wasn’t and Todd Pope purchased the platform with shareholders money.
Asensus; Now continues with the same old product and a 3 year old employee that was promoted to CEO after Todd Pope and Joseph Slattery left the company two years ago.
Welcome Anthony Fernando, you were in charge of selling Senhance worldwide and you never registered a single commercial sale. Ever.
Go to PubMed (dot com) and research Telap ALF X and Senhance.
